Novogen oncology spin-out MEI acquires pracinostat as S*BIO divests more assets
This article was originally published in Scrip
The publicly-traded Novogen oncology spin-out MEI Pharma has acquired pracinostat (SB939), an oral histone deacetylase (HDAC) inhibitor, for just $500,000 in MEI stock upfront, from Singapore-based S*BIO, as the private company's investors divest the last of its cancer drug assets.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.